Waldenströms macroglobulinaemia and intravenous contrast media.
In vivo and in vitro studies have been performed in a group of patients with immunoproliferative diseases to evaluate the risk of serious reactions due to serum jelling after intravenous injection of iodinated contrast media. Sol-jell convertion and/or turbidimetric variations have not been observed when either sera or plasmas have been mixed with variable amounts of a methylglucamine salt of ioglycamic acid (MGI) and other compounds. In addition, no side-effects have been clinically recorded in three patients with Waldenströms macroglobulinaemia (WM) whose sera and/or plasmas had been studied in vitro, when they have been submitted to intravenous contrast examinations. The results suggest that there is not an evidence of a relationship between iodinated contrast media and fatal reactions due to sol-jell alterations in patients with WM and therefore a radiological examination using contrast media may be carried out in those patients.
D003287:Contrast Media / Q000009:adverse effects*; D003450:Cryoglobulins / Q000032:analysis; D005782:Gels; D006801:Humans; D006847:Hydrocarbons, Iodinated / Q000009:adverse effects*; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D066298:In Vitro Techniques; D007275:Injections, Intravenous; D007458:Iodipamide / Q000009:adverse effects / Q000494:pharmacology; D009101:Multiple Myeloma / Q000097:blood; D010265:Paraproteinemias / Q000097:blood; D008258:Waldenstrom Macroglobulinemia / Q000097:blood*
D003287:Contrast Media; D003450:Cryoglobulins; D005782:Gels; D006847:Hydrocarbons, Iodinated; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007458:Iodipamide